TORONTO, Aug. 11, 2016 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, announced that its Chief Science Officer, Dr. Neil Cashman, is presenting today as an invited speaker at the Zing Propagation in Neurodegenerative Disease Conference held in Dublin, Ireland between August 8-11, 2016. Dr. Cashman's oral presentation is entitled "Prion-like Propagation of SOD1 Misfolding in Amyotrophic Lateral Sclerosis (ALS)".
Commenting on the presentation, Dr. Cashman stated: "Our research indicates that misfolded TDP43 behaves in a prion-like manner, causing normal human SOD1, a ubiquitous free-radical defense enzyme, to misfold via direct intermolecular interaction. We have concluded that SOD1 misfolding can be triggered by abnormalities in other ALS-implicated proteins, including TDP43, and that misfolded SOD1 can propagate within and between cells, a key feature of ALS pathophysiology. These new findings support ProMIS' ALS program targeting neurotoxic, prion-like forms of both SOD1 and TDP43."
The Zing Propagation in Neurodegenerative Disease Conference brings together neurologists, neuropathologists and basic scientists with experience across a wide variety of neurodegenerative diseases. A key objective of this meeting is to discuss the cell-to-cell spreading of prion-like proteins and their implications in neurodegenerative disease progression, with a goal of building relevant disease models and identifying therapeutic strategies.
About ProMIS Neurosciences, Inc.
The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.
ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates—to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has three preclinical monoclonal antibody therapeutics against this target.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
The information in this release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information please consult the Company's website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
SOURCE ProMIS Neurosciences Inc.
For further information: NATIONAL Equicom: Michael Moore: email@example.com; Abby Garfunkel: firstname.lastname@example.org; or contact Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.email@example.com